News About: Pharm. Industry
KGC Sang-A to acquire Kyungnam Pharm
The Korea Green Cross Sang-A Pharm said it has acquired 70 percent stake of Kyungnam Pharm for taking over the latter's managerial right and the remaining equities would be reserved to the existing Kyungnam's sharehol...
Males suffering from erectile dysfunction prefer Cialis
A number of males with erectile dysfunction tend to prefer Cialis than Viagra due to the former's long duration of action, rapid onset of efficacy and less side effects, a recent symposium said.
In the September 2 ...
Drug export and import in 1/2 this year on backward steps.
The bulk drug export and import during the first half of this year showed very slow.
A statistics compiled by the Korea Pharmaceutical Trade Association (President: Chung Seung-whan) over the drug export and import...
Pfizer Korea opts for same pricing strategy on Lipitor
Pfizer Korea said it will soon launch Lipitor 40 mg, lipid-lowering agent, at the same level as Lipitor 20 mg in the domestic market.
Earlier, the company lowered voluntarily the original insurance price of Lipitor...
Pfizer Korea's confidence on Viagra sales
Although a number of entrants will intensify their fierce competition in domestic market for erectile dysfunction drugs, Pfizer Korea that said it will welcome newcomers and that Viagra may lead the market as a foreru...
KHIDI transferring technology to Biolab.
The Health Industry Technology Transfer Center of the KHIDI succeeded in coordinating a technology transfer on Aug. 25 from Prof. Han Eung-soo of Agricultural College who developed the technology for "the prevention a...
BMS Korea to withdraw taxol from Zuellig Korea
BMS Korea said it will decide on the issue to withdraw taxol from Zuellig Korea upon a newly-appointed president's return from overseas trip on September 2, while it sticks to outsourcing its OTC business to Zuellig K...
New and modified drugs researches invigorated.
Many leading domestic drug companies are reinforcing their R&D investment for the new and modified drugs. Especially many modified new drugs seem to come out next year.
According to Yakup Press survey against the l...
Domestic pharmaceutical firms urged to augment actual R&D investment
Although some leading pharmaceutical firms have embarked for their sizable investments in R&D new drug projects, the majority of domestic pharmaceutical firms have concentrated their R&D outlays on labor costs...
Domestic pharmaceutical industry expected to suffer 30.0 billion damage due to price cutbacks
The combined loses suffered by pharmaceutical firms due to the government's price cutbacks of drugs based on the actually-transacted minimum drug price system will reach 30.0 billion (each firm will suffer a loss rang...
